公开(公告)号：US11338035B2

公开(公告)日：2022-05-24

申请号：US16847229

申请日：2020-04-13

Applicant: RINAT NEUROSCIENCE CORP.

Inventor： Yasmina Noubia Abdiche ,  Helen Kim Cho ,  Wei-Hsien Ho ,  Karin Ute Jooss ,  Arvind Rajpal ,  Sawsan Youssef

IPC: C07K16/28 ,  A61K39/395 ,  A61P35/00 ,  A61K39/39 ,  A61K45/06 ,  A61K39/00

Abstract: The present invention provides antagonizing antibodies that bind to programmed cell death protein 1 (PD-1) and methods of using same. The anti-PD-1 antibodies can be used therapeutically alone or in combination with other therapeutics to treat cancer and other diseases.

公开(公告)号：US20220249657A1

公开(公告)日：2022-08-11

申请号：US17725199

申请日：2022-04-20

Applicant: RINAT NEUROSCIENCE CORP.

Inventor： Yasmina Noubia Abdiche ,  Helen Kim Cho ,  Wei-Hsien Ho ,  Karin Ute Jooss ,  Arvind Rajpal ,  Sawsan Youssef

IPC: A61K39/39 ,  A61K39/395 ,  A61K45/06 ,  A61K39/00 ,  C07K16/28

Abstract: The present invention provides antagonizing antibodies that bind to programmed cell death protein 1 (PD-1) and methods of using same. The anti-PD-1 antibodies can be used therapeutically alone or in combination with other therapeutics to treat cancer and other diseases.

公开(公告)号：US20200368349A1

公开(公告)日：2020-11-26

申请号：US16847229

申请日：2020-04-13

Applicant: RINAT NEUROSCIENCE CORP.

Inventor： Yasmina Noubia Abdiche ,  Helen Kim Cho ,  Wei-Hsien Ho ,  Karin Ute Jooss ,  Arvind Rajpal ,  Sawsan Youssef

IPC: A61K39/39 ,  A61K39/395 ,  A61K45/06 ,  A61K39/00 ,  C07K16/28

Abstract: The present invention provides antagonizing antibodies that bind to programmed cell death protein 1 (PD-1) and methods of using same. The anti-PD-1 antibodies can be used therapeutically alone or in combination with other therapeutics to treat cancer and other diseases.

公开(公告)号：US10660953B2

公开(公告)日：2020-05-26

申请号：US16188120

申请日：2018-11-12

Applicant: RINAT NEUROSCIENCE CORP.

Inventor： Yasmina Noubia Abdiche ,  Helen Kim Cho ,  Weihsien Ho ,  Karin Ute Jooss ,  Arvind Rajpal ,  Sawsan Youssef

IPC: C07K16/28 ,  A61K39/395 ,  A61K39/39 ,  A61K45/06 ,  A61K39/00

Abstract: The present invention provides antagonizing antibodies that bind to programmed cell death protein 1 (PD-1) and methods of using same. The anti-PD-1 antibodies can be used therapeutically alone or in combination with other therapeutics to treat cancer and other diseases.